Stone Pharmaceutical Group: Monkeypox mRNA vaccine has received clinical trial approval from the U.S. FDA.

Shijiazhuang Pharmaceutical Group announced that the class 1 new drug SYS6037 injection, developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences as a preventive biological product, has been approved by the U.S. Food and Drug Administration for clinical trials in the United States. Preclinical studies have shown that, compared to live attenuated vaccines, this product has superior immunogenicity and protection efficacy, and demonstrates broad cross-reactivity against various orthopoxvirus antigens.